Generic filters
Filter by content type
Taxonomy terms

VIRX – Viracta Therapeutics Inc


Subscribe for full access

Unlock Industry-grade Shariah Compliance for US, UK, Canada, Germany, GCC, Europe and India. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.

Get started from just $1/month


Recommendation Rating







1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Analysts’ Price Targets

Mean 21.4

Low: 10

High: 36

Total Analysts: 4

Company Profile

Viracta Therapeutics, Inc. is a clinical-stage, precision oncology company. The Company is focused on advancing new medicines for the treatment of virus-associated malignancies. The Company conducts clinical trials for its combination product candidate as a therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma. Its lead product candidate is an all-oral combination therapy of its investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively referred to as Nana-val). Nana-val is being evaluated in multiple ongoing clinical trials, including Phase II basket trial for the treatment of multiple subtypes of relapsed/refractory EBV+ lymphoma (NAVAL-1), as well as a Phase Ib/II trial for the treatment of EBV+ recurrent and other EBV+ solid tumors. The Company’s product candidate pipeline also includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor and VRx-510, a preclinical-stage PDK-1 inhibitor.

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan